ANTI-FIBROTIC THERAPY MODULATES MORTALITY RISK ASSOCIATED WITH CIRCULATING PLASMA BIOMARKERS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

被引：1
|
作者：
Oldham, Justin
Alqalyoobi, Shehabaldin
Adegunsoye, Ayodeji
Linderholm, Angela
Hrusch, Cara
Pugashetti, Janelle
Boctor, Noelle
Sperling, Anne
Strek, Mary
Noth, Imre
机构：
来源：
CHEST | 2019年 / 156卷 / 04期
关键词：
D O I：
10.1016/j.chest.2019.08.305
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：258A / 259A
页数：2
相关论文
共 50 条
  • [21] DISEASE PROGRESSION IN IDIOPATHIC PULMONARY FIBROSIS UNDER ANTI-FIBROTIC TREATMENT
    Cilli, Aykut
    Uzer, Fatih
    [J]. SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023, 40 (03)
  • [22] Real-world study evaluating anti-fibrotic therapy on survival in idiopathic pulmonary fibrosis
    Robertson, Lucy
    Barnes, Joshua
    Rogers, Kirstie
    Thillai, Muhunthan
    Parfrey, Helen
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [23] A HUMAN MODEL OF LUNG FIBROSIS FOR THE ASSESSMENT OF ANTI-FIBROTIC STRATEGIES IN IDIOPATHIC PULMONARY FIBROSIS
    Roach, K. M.
    Tongue, P.
    Castells, E.
    Elliot, G.
    Marshall, H.
    Richardson, M.
    Mason, S.
    Chachi, L.
    Bradding, P.
    [J]. THORAX, 2019, 74 : A56 - A57
  • [24] Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Hostettler, Katrin
    Papakonstantinou, Eleni
    Klagas, Ioannis
    Bonovolias, Ioannis
    Sun, Qingzhu
    Tamm, Michael
    Lambers, Christopher
    Roth, Michael
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [25] Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Hostettler, Katrin E.
    Zhong, Jun
    Papakonstantinou, Eleni
    Karakiulakis, George
    Tamm, Michael
    Seidel, Petra
    Sun, Qingzhu
    Mandal, Jyotshna
    Lardinois, Didier
    Lambers, Christopher
    Roth, Michael
    [J]. RESPIRATORY RESEARCH, 2014, 15
  • [26] Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Katrin E Hostettler
    Jun Zhong
    Eleni Papakonstantinou
    George Karakiulakis
    Michael Tamm
    Petra Seidel
    Qingzhu Sun
    Jyotshna Mandal
    Didier Lardinois
    Christopher Lambers
    Michael Roth
    [J]. Respiratory Research, 15
  • [27] Characteristics Of Patients With Idiopathic Pulmonary Fibrosis (ipf) Receiving Approved Anti-Fibrotic Therapies In The Us
    Gamerman, V.
    Salisbury, M.
    Culver, D.
    Leonard, T.
    Neely, M. L.
    Yow, E.
    Conoscenti, C. S.
    Palmer, S.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [28] Anastomotic Outcomes in Idiopathic Pulmonary Fibrosis Patients Receiving Anti-Fibrotic Therapy: Experience of the Australian Lung Transplant Collaborative
    Mackintosh, J.
    Munsif, M.
    Thomson, C.
    Musk, M.
    Snell, G.
    Glanville, A.
    Chambers, D.
    Hopkins, P.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S89 - S90
  • [29] Real-life survival of idiopathic pulmonary fibrosis with anti-fibrotic medication
    Bleinc, Alexandre
    Blin, Timothee
    Legue, Sylvie
    Mankikian, Julie
    Plantier, Laurent
    Marchand-Adam, Sylvain
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2023, 40 (05) : 371 - 381
  • [30] Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world
    Sugimoto, Chikatoshi
    Inoue, Yoshikazu
    Arai, Toru
    Kasai, Takehiko
    Akira, Masanori
    Hayashi, Seiji
    Tachibana, Kazunobu
    Sasaki, Yumiko
    Takeuchi, Naoko
    Minomo, Syojiro
    Ikegami, Naoya
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50
12345